1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Italy To Relax Biosimilar Switching Rules In Cost-Savings Effort

 
• By Ian Schofield

The move towards greater acceptance of biosimilars is likely to be spurred by new guidance from the Italian regulatory agency AIFA giving more support to biosimilar switching, and by the declaration by a key European medical association that switching infliximab products in IBD patients is “acceptable.”

Reducing costs
Italy is encouraging biosimilar use to help reduce spending on biologic drugs

Italian medicines regulator AIFA is preparing to publish a revised version of its 2013 position paper on biosimilars that is expected to take a more relaxed stance towards the switching of patients from an originator drug to a biosimilar version.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics